Bio-Gene Moves Closer to Flavocide Filing and Qcide Japan Supply

Flavocide Submission Target Set for Q2 2027

Bio-Gene Technology Limited (ASX:BGT) is targeting Q2 2027 for its first Australian regulatory application for Flavocide, giving investors a clearer date for the next major step in the company’s development program. The target remains conditional on completing the remaining safety, metabolism, pharmacokinetic, physico-chemical and stability studies, as well as finalising the regulatory dossier for the Australian Pesticides and Veterinary Medicines Authority.

The in-life phases of the OECD 424 acute neurotoxicity study and OECD 443 extended one-generation reproductive toxicity study are complete. Draft preliminary reports are now undergoing scientific and technical review, a process Bio-Gene said is intended to ensure the data, interpretation and conclusions are accurately reflected before the reports are finalised.

The timetable is broadly consistent with the company’s earlier regulatory plan, while the stated target has shifted from March 2027 to the broader Q2 2027 quarter. That change does not indicate a regulatory outcome, but it leaves completion of the remaining studies and dossier preparation as the immediate execution tests.

Qcide Japan Supply Work Continues Without an Order Date

Bio-Gene is also working with Sumitomo Corporation and Nakashima Trading Co. on product planning, specifications, documentation and manufacturing steps for Qcide-based household insecticide products in Japan. The company has not yet agreed the timing of the first commercial order, so the Japanese opportunity remains a development and preparation milestone rather than reported revenue.

The work follows the Qcide Japan partnership, which earlier involved a targeted launch plan for the Japanese household nuisance insect market. During the quarter, Bio-Gene completed its 16th Qcide harvest in north Queensland, with analysis of the harvested oil underway.

Part of the latest harvest came from the first cut of trees planted in 2025. Those trees will coppice ahead of another harvest in Q2 2027, while intensified management of the seed production area is intended to support future plantation expansion. Bio-Gene says the typical interval from planting a new Eucalyptus cloeziana seedling to its first harvest is about 18 months, making seed production a practical constraint on any significant increase in Qcide output.

Tick Data Adds Laboratory Evidence for Flavocide

Research conducted by Purdue University and published after quarter end in the peer-reviewed journal Ticks and Tick-borne Diseases found that a prototype Flavocide formulation produced more than 90% mortality of deer tick nymphs 24 hours after exposure under laboratory conditions. Residual testing recorded more than 70% mortality for up to four weeks.

The published findings describe potential for extended tick control, but also call for further laboratory work at lower active-ingredient concentrations before field testing. The results therefore add evidence to Flavocide’s development case without establishing field performance or regulatory approval.

Capital Raise Extends Development Work, Not Commercial Runway

Bio-Gene completed the second tranche of its placement and share purchase plan underwriting during the quarter, taking total gross proceeds to approximately $3.275 million before costs. The company issued 51.98 million ordinary shares and 69.22 million options exercisable at $0.035 and expiring on 15 October 2027. The completed $3.275m capital raise was previously reported as funding for Flavocide studies, Qcide production scale-up and commercial activities.

At 30 September, Bio-Gene held A$2.103 million in cash after using A$966,000 in operating activities during the quarter. It received A$162,000 in government grants and tax incentives during the period, while a further $343,000 R&D tax incentive relating to FY26 expenditure arrived after quarter end and is excluded from the reported cash balance.

On the quarter’s operating cash use, the Appendix 4C calculates estimated funding of 2.18 quarters, with no debt facilities reported. That is a simple cash-duration measure rather than a forecast of future funding needs, and it excludes any commercial receipts, changes in spending or additional capital. The next useful evidence will be whether Qcide’s first Japanese order is dated and whether the remaining Flavocide studies stay on track for the Q2 2027 submission target.